{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.7","value":"49.0"},{"groupId":"OG002","spread":"8.80","value":"69.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"Evaluate the Terminal elimination half-life \\[t1/2\\] of ONM-100 at the dose(s) and imaging schedule(s) post dose used to assess optimal imaging in Part 1 and Part 2.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"All patients in this arm received IV administration of ONM-100 at a dose of 1 mg/kg.","id":"OG000","title":"ONM-100 at Dose of 1 mg/kg"},{"description":"All patients in this arm received IV administration of ONM-100 at a dose of 2 mg/kg.","id":"OG001","title":"ONM-100 at a Dose of 2 mg/kg"},{"description":"All patients in this arm received IV administration of ONM-100 at a dose of 3 mg/kg.","id":"OG002","title":"ONM-100 at a Dose of 3 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis population comprised 19 patients for whom concentration data were available. Due to the sparse plasma concentrations for the majority of patients, with the exception of Cmax and Tmax, it was not possible to estimate all parameters for all patients.","reportingStatus":"POSTED","timeFrame":"6 days","title":"Evaluate Pharmacokinetic Parameters: t1/2","type":"SECONDARY","unitOfMeasure":"hr"}